BioMarin Director Athena Countouriotis Receives 7,490 Restricted Stock Units

This Form 4 filing reports that Athena Countouriotis, a director of BioMarin Pharmaceutical Inc., received 7,490 restricted stock units on June 2, 2026. The transaction was an award of equity compensation (transaction code A) at no cost to the director. Following this award, Countouriotis now holds 21,040 shares of BioMarin common stock. The filing notes that these are restricted stock units granted on June 2, 2026, and the price is not applicable as this represents an equity award rather than a market purchase. The filing was signed by attorney-in-fact Tae Sang Yoo on June 4, 2026, and relates to BioMarin Pharmaceutical Inc. (ticker: BMRN).